Morgan Stanley’s Palisade Bio PALI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $5.17M | Sell |
2,474,069
-2,077,464
| -46% | -$4.09M | ﹤0.01% | 4197 |
|
|
2026
Q1 | $7.97M | Buy |
4,551,533
+409,087
| +10% | +$744K | ﹤0.01% | 3765 |
|
|
2025
Q4 | $9.73M | Buy |
4,142,446
+4,133,828
| +47,967% | +$7.95M | ﹤0.01% | 3638 |
|
|
2025
Q3 | $7.41K | Buy |
8,618
+8,611
| +123,014% | +$6.73K | ﹤0.01% | 6981 |
|
|
2025
Q2 | $5 | Sell |
7
-621
| -99% | -$445 | ﹤0.01% | 8048 |
|
|
2025
Q1 | $428 | Buy |
628
+621
| +8,871% | +$734 | ﹤0.01% | 7395 |
|
|
2024
Q4 | $12 | Sell |
7
-133
| -95% | -$350 | ﹤0.01% | 7903 |
|
|
2024
Q3 | $497 | Hold |
140
| – | – | ﹤0.01% | 7299 |
|
|
2024
Q2 | $630 | Sell |
140
-1
| -0.7% | -$5 | ﹤0.01% | 7205 |
|
|
2024
Q1 | $841 | Hold |
141
| – | – | ﹤0.01% | 7191 |
|
|
2023
Q4 | $1.24K | Buy |
141
+5
| +4% | +$44 | ﹤0.01% | 7110 |
|
|
2023
Q3 | $1.19K | Hold |
136
| – | – | ﹤0.01% | 7214 |
|
|
2023
Q2 | $3.47K | Sell |
136
-79
| -37% | -$1.97K | ﹤0.01% | 7066 |
|
|
2023
Q1 | $11.4K | Buy |
215
+68
| +46% | +$2.39K | ﹤0.01% | 6838 |
|
|
2022
Q4 | $11.5K | Buy |
147
+59
| +67% | +$3.42K | ﹤0.01% | 6885 |
|
|
2022
Q3 | $6K | Buy |
88
+79
| +878% | +$16.7K | ﹤0.01% | 7214 |
|
|
2022
Q2 | $3K | Hold |
9
| – | – | ﹤0.01% | 7521 |
|
|
2022
Q1 | $7K | Hold |
9
| – | – | ﹤0.01% | 7508 |
|
|
2021
Q4 | $9K | Buy |
9
+3
| +50% | +$5.24K | ﹤0.01% | 7506 |
|
|
2021
Q3 | $12K | Buy |
6
+1
| +20% | +$2.21K | ﹤0.01% | 7274 |
|
|
2021
Q2 | $16K | Buy |
+5
| New | +$22.7K | ﹤0.01% | 7074 |
|
|
2021
Q1 | – | Hold |
0
| – | – | – | 7216 |
|
|
2020
Q4 | – | Hold |
0
| – | – | – | 7090 |
|
|
2020
Q3 | – | Hold |
0
| – | – | – | 6805 |
|
|
2020
Q2 | – | Hold |
0
| – | – | – | 6689 |
|
|
2020
Q1 | – | Hold |
0
| – | – | – | 6662 |
|
|
2019
Q4 | – | Hold |
0
| – | – | – | 6728 |
|
|
2019
Q3 | – | Hold |
0
| – | – | – | 6717 |
|
|
2019
Q2 | – | Hold |
0
| – | – | – | 6709 |
|
|
2019
Q1 | – | Hold |
0
| – | – | – | 6526 |
|
|
2018
Q4 | – | Hold |
0
| – | – | – | 6685 |
|
|
2018
Q3 | – | Hold |
0
| – | – | – | 6638 |
|
|
2018
Q2 | – | Hold |
0
| – | – | – | 6510 |
|
|
2018
Q1 | – | Hold |
0
| – | – | – | 6393 |
|
|
2017
Q4 | – | Hold |
0
| – | – | – | 6236 |
|
|
2017
Q3 | – | Hold |
0
| – | – | – | 6259 |
|
|
2017
Q2 | – | Hold |
0
| – | – | – | 6113 |
|
|
2017
Q1 | – | Hold |
0
| – | – | – | 6184 |
|
|
2016
Q4 | – | Hold |
0
| – | – | – | 6305 |
|
|
2016
Q3 | – | Hold |
0
| – | – | – | 6235 |
|
|
2016
Q2 | – | Hold |
0
| – | – | – | 6262 |
|
|
2016
Q1 | – | Hold |
0
| – | – | – | 6050 |
|
|
2015
Q4 | – | Hold |
0
| – | – | – | 5966 |
|
|
2015
Q3 | – | Hold |
0
| – | – | – | 5868 |
|
|
2015
Q2 | – | Hold |
0
| – | – | – | 5402 |
|
|
2015
Q1 | – | Hold |
0
| – | – | – | 5673 |
|
|
2014
Q4 | – | Hold |
0
| – | – | – | 4954 |
|
|
2014
Q3 | – | Hold |
0
| – | – | – | 4587 |
|
|
2014
Q2 | – | Hold |
0
| – | – | – | 4263 |
|
|
2014
Q1 | – | Hold |
0
| – | – | – | 3732 |
|
|
2013
Q4 | – | Hold |
0
| – | – | – | 5022 |
|
|
2013
Q3 | – | Hold |
0
| – | – | – | 5177 |
|
Other funds holding PALI
SCM
BGI
JT
OCA
PA
RCM
Morgan Stanley's PALI Position: Q2 2026 in Review
Morgan Stanley reduced its Palisade Bio (PALI) stake by 46% in Q2 2026, selling an estimated $4.09M and leaving 2,474,069 shares worth $5.17M. The position accounts for ﹤0.01% of the portfolio, ranked #4197.
Morgan Stanley first reported a position in PALI in Q2 2021 and has held it in 21 quarters since. The position peaked at $9.73M in Q4 2025. 124 funds tracked by Wall St. Rank hold PALI as of Q2 2026.
- Morgan Stanley held 2,474,069 shares of Palisade Bio worth $5.17M as of Q2 2026.
- Morgan Stanley sold 2,077,464 Palisade Bio shares in Q2 2026, an estimated $4.09M.
- Palisade Bio made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #4197 holding.
- Morgan Stanley first reported a position in Palisade Bio in Q2 2021 and has held it in 21 quarters since.
- Morgan Stanley's Palisade Bio position peaked at $9.73M in Q4 2025.
- 124 funds tracked by Wall St. Rank held Palisade Bio as of Q2 2026.
Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.